Gilead Sciences Stock (US3755581036): Trading lower as the shares go ex-dividend

Gilead Sciences is in focus on June 15, 2026, after the stock traded at $124.11 in Nasdaq trading and was listed among names going ex-dividend today.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 15, 2026 at 10:27 PM ET. Details in the imprint.

Gilead Sciences is in focus after the stock traded at $124.11 in Nasdaq trading at 3:53 PM on June 15, 2026, down 1.2% on the session, according to finanzen.net. Wallstreet Online also listed Gilead Sciences among the stocks going ex-dividend today, with a quarterly dividend of $0.82 per share.

What is driving the move

The move appears tied to the ex-dividend date rather than a new earnings release or analyst action in the search results. Ex-dividend trading often changes the headline price because new buyers are no longer entitled to the upcoming payout, which can pressure the quote even when the operating story has not changed.

At the same time, the decline was not extreme: the stock was still only 1.2% lower when the cited market update was published, and the intraday range shown in the same report reached a low of $122.70. That puts the session in the category of a modest pullback rather than a sharp re-rating.

Gilead trades on Nasdaq and is a member of the Nasdaq Composite, so the stock's move is being measured against a broader U.S. large-cap technology and healthcare benchmark rather than a narrow company-specific trading lane.

The dividend notice matters because it gives the price action a calendar-driven explanation that is independent of new business news. In practical terms, the market is adjusting to the payout schedule while still waiting for a fresh catalyst that would change the outlook more materially.

Gilead Sciences at a glance

• Name: Gilead Sciences
• Industry: Biopharmaceuticals
• Headquarters: Foster City, California, United States
• Core markets: HIV, hepatitis, oncology, and cell therapy
• Revenue drivers: Antiviral medicines, oncology treatments, and cell therapy products
• Listing: Nasdaq, ticker GILD
• Trading currency: US dollars

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.